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Abstract
Objective To assess the claim in a Cochrane review that mammographic
breast cancer screening could be doing more harm than good by
updating the analysis in the Forrest report, which led to screening in the
United Kingdom.
Design Development of a life table model, which replicated Forrest’s
results before updating and extending them with data from relevant
systematic reviews, trials, and other models based on purposive literature
searches.
Participants Women aged 50 and over invited for breast cancer
screening.
Main outcome measures Quality adjusted life years (QALYs), combining
life years gained from screening with losses of quality of life from false
positive diagnoses and surgery.
Results Inclusion of the effects of harms reduced the updated estimate
of net cumulative QALYs gained after 20 years from 3301 to 1536 or by
more than half. The best estimates from the Cochrane review generated
negative QALYs for the first seven years of screening, 70 QALYs after
10 years, and 834 QALYs after 20 years. Sensitivity analysis showed
these results were robust to a range of assumptions, particularly up to
10 years. It also indicated the importance of the level and duration of
harms from surgery.
Conclusions This analysis supports the claim that the introduction of
breast cancer screening might have caused net harm for up to 10 years
after the start of screening.
Introduction
The Forrest report in 1986,
1 which led to the introduction of
mammographic breast screening in the United Kingdom,
analysed the costs and benefits in terms of quality adjusted life
years (QALYs). One of the earliest uses of QALYs to guide
policy, it suggested that screening would reduce the death rate
from breast cancer by almost one third with few harms and at
low cost (for details see appendix on bmj.com).
The key data used in the Forrest report were drawn from two
randomisedtrials,theSwedishtwocountiestrial
2andtheHealth
Insurance Plan (HIP) New York trial.
3 The Forrest report
claimed that overdiagnosis was not a problem, based on the
New York trial, but noted that the Swedish trial found possible
overdiagnosis of 20%. It stated that “further follow up is
required to find out whether this excess persisted.” We have
updatedtheForrestreport’sestimatesformortalityandextended
them to include the effects of false positives and overdiagnosis.
Since the Forrest report, the harms of mammographic breast
cancer screening have been acknowledged. A WHO report
defined false positives and overdiagnosis:
“The term false positive refers to an abnormal
mammogram (one requiring further assessment) in a
woman ultimately found to have no evidence of
cancer. Overdiagnosis refers to the diagnosis and
treatment of cancer that would never have caused
symptoms. Thus a false positive result can be found
only in a woman without cancer, while overdiagnosis
can only be made for women with cancer.”
4
It went on to note that “overdiagnosis is a foreign concept to
most prospective screenees (and many clinicians).”
TheWHOreportnotedthataconsiderablepartofoverdiagnosis
involved ductal carcinoma in situ, which accounts for around a
fifthofmammographicallydetectedcancers.Whilethisisarisk
factor for breast cancer, only a minority of these develop into
breast cancer. Indeed the inclusion of the term “carcinoma” in
ductal carcinoma in situ has been questioned.
5
The WHO report claimed that the success of breast cancer
screening programmes should be assessed only in terms of
mortality: “Screening programmes should ultimately be
monitored in terms of deaths, the measure directly related to
the purpose of screening.” A focus solely on deaths, however,
implies ignoring harms to the living.
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Research
RESEARCHGøtzsche and Nielsen’s Cochrane review
6 raised the disturbing
possibility that mammographic breast cancer screening could
bedoingmoreharmthangood.Thiswasbecauseoftheirlower
estimate of the reduction in mortality from breast cancer and
their inclusion of the harms from overtreatment. They said that
“this means that for every 2000 women invited for screening
throughout 10 years, one will have her life prolonged, and 10
healthy women, who would not have been diagnosed if there
had not been screening, will be diagnosed as breast cancer
patients and will be treated unnecessarily. Furthermore, more
than 200 women will experience important psychological
distress for many months because of false positive findings. It
isthusnotclearwhetherscreeningdoesmoregoodthanharm.”
6
Their meta-analysis included eight randomised trials, three of
which they considered adequately randomised and five
suboptimally randomised. Only the suboptimally randomised
trials found a significant effect of screening on deaths ascribed
tobreastcancer.Foralltheeighttrialstakentogethertherelative
risk reduction for mortality from breast cancer was 19% (95%
confidence interval 26% to 13%) after 13 years. Given the
quality of the evidence, Gøtzsche and Nielsen’s best estimate
of the effect of screening was a 15% decline in mortality.
The increased risk of surgery was the basis of Gøtzsche and
Nielsen’sestimateofunnecessarytreatment.Fourtrialsprovided
data on breast operations (mastectomies and lumpectomies),
with more performed in the screened groups than in the control
groups: the relative risk increase was 31% (22% to 42%) for
the two adequately randomised trials and 35% (26% to 44%)
forallfourtrials.Forfalsepositiveresults,GøtzscheandNielsen
stated “it seems that screening inflicts important psychological
distress for many months on more than a 10th of the healthy
population of women who attend a screening program.”
Asystematicreviewandmeta-analysisbyNelsonandcolleagues
for the US Preventive Services Task Force independently
analysed the same eight clinical trials in the Cochrane review
but by age group.
7 8 This put the reduction in mortality from
breast cancer at 15% for those aged 39-49, 14% for those aged
50-59, and 32% for those aged 60-69. It used US registry data
to suggest that about 10% of those screened would have a false
positive result requiring further investigation.
7 It differed from
the Cochrane review in relation to overdiagnosis. “Rates of
overdiagnosis vary from less than 1% to 30% with most from
1% to 10%. Estimates differ by outcome (invasive vs in situ
breast cancer), by whether cases are incident or prevalent, and
by age. The studies are too heterogeneous to combine
statistically.”
7 These studies, it should be noted, included both
randomised trials and observational studies.
Thus the two systematic reviews agreed that screening reduced
mortality from breast cancer but differed in how much. Nelson
and colleagues estimated a false positive rate around 10% per
roundofscreening,whileGøtzscheandNielsenputitataround
10% over 10 years. Only Gøtzsche and Nielsen provided data
on the increased relative risk of surgery with screening, with
two estimates: 31% based on the better quality trials and 35%
based on all trials reporting this outcome.
WeassessedtheclaimofGotzscheandNielsenbyupdatingthe
Forrest report framework, extended to include harms. The
Forrest report used life tables to estimate the number of women
surviving by year up to 15 years in two cohorts aged 50, only
one of which was screened. Deaths could be from breast cancer
or all other causes. Baseline mortality and the reduction from
triennial breast cancer screening were based on the two
randomised controlled trials then available. The difference in
life years between the two cohorts after 15 years was expressed
in QALYs by reducing their quality of life by 8% to reflect the
effects of treatment.
Methods
The Southampton model used the same life table approach as
Forrest to estimate life years. To ensure that the Southampton
model was fully compatible, we confirmed that use of Forrest
inputs generated the same number of deaths in our model.
Forresttookbaselinemortalityfrombreastcancerfromthetwo
trials then available but acknowledged that as this was below
the English mortality rate from breast cancer, his results were
underestimates. In updating Forrest, we corrected this by using
themortalityratefrombreastcancerforEngland.
9Wealsotook
the baseline risk of surgery for breast cancer from the English
NHS.
10 11 Data for both these baselines were for 1985, the latest
year before screening for which we could locate data. These
changes meant more favourable results for screening than if we
used the control arms of trials as baselines.
We drew parameter inputs for the Southampton model (table
1⇓) from the published literature, giving priority to systematic
reviews, followed by randomised clinical trials and other
published models, and then observational data supplemented
by clearly stated assumptions when necessary. Sensitivity
analysisvariedmeanestimatestotheir95%confidenceintervals
and other inputs by ±33%. The results of individual sensitivity
analysesarereportedintheappendixonbmj.com.Probabilistic
sensitivity analysis varied key inputs simultaneously by
sampling from their probability distributions for 10 000
iterations.
All the input values are listed in table 1 with sources and
discussed more fully in the appendix on bmj.com. In brief, the
changed relative risks for breast cancer mortality and surgery
fromscreeningwerebasedonthemeta-analysesoftherelevant
trials.
6-8 The losses of quality of life from false positive results
and surgery were based on a systematic review, supplemented
by relevant randomised trials and values used in previous
models. The extent and duration of the loss of quality of life
from surgery have been least researched. We assumed a 6%
permanent loss from surgery, less than in the Forrest report but
informed by recent randomised trials.
12 13 Sensitivity analyses
explored changing the extent and duration of these and other
values. Figure 1 illustrates the modelling approach⇓.
Setting, participants, and outcome measures
The setting was England. The outcomes of 100 000 women
aged 50 were modelled in two cohorts, one screened the other
not. The outcome measures were deaths from breast cancer,
deaths from all other causes, and the number of women having
false positive diagnoses and surgery, which we combined into
the main outcome—quality adjusted life years (QALYs).
Results
Figure 2 graphically presents the five scenarios⇓, and table 2
summarises the results⇓. Scenario 1 shows the QALY gains
thatForrestwouldhavegotifhehadusedEnglishbreastcancer
mortality rates as baseline with his risk reductions. Scenario 2
updates this with the reduction in mortality from breast cancer
for all ages from all eight trials. The losses of quality of life
fromsurgeryandfalsepositivediagnoseswereaddedinscenario
3.Scenario4usedthereductioninmortalityfrombreastcancer
suggested by Gøtzsche and Nielsen.
6 In scenario 5, we used the
reductions in mortality from breast cancer by age group from
Nelson et al.
7 8 The results are based on 100 000 women being
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RESEARCHinvited for mammographic screening, with 73% attending, and
are presented for each year up to 20 years after the entry to the
screening programme.
Scenario 1 accumulated just over 3300 net QALYs after 20
years. This is what Forrest would have got had he used as
baseline the breast cancer mortality rate for England and the
mortality reduction from the two trials. When we updated the
estimate for reduction in breast cancer mortality for all ages,
with the meta-analysis of the eight trials (scenario 2), the net
cumulative QALY gain at 20 years fell to around 3100 QALYs
or by about 6%.When we added harms in scenario 3, this was
reducedtojustover1500QALYsorbyhalf.Whenwechanged
the reduction in mortality from breast cancer to that suggested
by Gøtzsche and Nielsen.
6 the net QALYs at year 20 fell to 834
(scenario 4). Scenario 5, based on the reductions in mortality
from breast cancer by age group suggested by Nelson et al,
7 8
generated 1685 QALYs by year 20.
Scenarios 3, 4, and 5 had negative cumulative QALY values
for the first four, seven, and eight years, respectively, but had
positivevaluesafter10years.Theharmsfromsurgeryandfalse
positive diagnoses impacted from the start because they were
linkedtoeachroundofscreening.Mortalityfrombreastcancer,
however, was reduced only after several years but accumulated
over time so that positive net QALY applied by 10 and




four key parameters (reduced mortality from breast cancer,
increased surgery for breast cancer, and losses of quality of life
from false positive results and from surgery) in a probabilistic
sensitivity analysis for scenario 3 (Forrest updated including
harms), the net cumulative gain in QALYs after 20 years was
between 771 and 2136 (mean 1532), with lower values in the
earlier years (fig 3⇓). The mean number of years with negative
QALYs was four, with a range of two to nine.
We did not include the duration of harms from surgery in the
probabilistic sensitivity analysis because of uncertainty about
the appropriate distribution. Instead we used deterministic
sensitivity analyses to explore reducing the duration of harms
from surgery, assumed as permanent in the base case, to five
and10years(seeappendixonbmj.com).Thisledtounchanged
net QALYs up to five and 10 years but with more QALYs over
longer periods.
Discussion
Assessment of the effects of mammographic breast screening
in terms of mortality or life years inevitably shows positive
benefits because of the omission of harms. Despite its espousal
of a QALY framework, the Forrest report focused mainly on
life years gained, which it adjusted for quality of life only from
necessary surgery and ignored all other harms. Our analysis
shows that inclusion of the harms from false positive results
and unnecessary surgery reduced the benefits of screening by
about half with negative net QALYs in the early years after the
introduction of screening.
We assumed that the loss of quality of life in women who had
unnecessary surgery was the same as for those who had had
“necessary” surgery. A key feature of overtreatment is that
individuals affected cannot be identified. Of Gøtzsche and
Nielsen’s10womenwhohadunnecessarysurgery,allbelieved
that it was necessary.
6 This has been dubbed the paradox of
overtreatment—“overdiagnosis and overtreatment create a
paradoxical popularity because each individual justifies their
experience by believing they have had a dramatic benefit.”
20
The more people are (over)treated, the more people think
screening saved their lives.
Would knowing whether or not treatment was necessary affect
quality of life? None of the surveys of quality of life included




problems of measuring quality of life in cancer screening are
considerable,
21 ignoring overtreatment is inexcusable.
Ways of reducing the harms from screening might include less
frequentscreens,particularlyforyoungerwomen.Whilefurther
modelling might explore the clinical and cost effectiveness of
various options, conclusions will inevitably be limited without





cancer in 1985 was higher in England than in those trials, we
took as baseline the rate for England for 1985, before screening
wasintroduced.Wehaveassumedthattheriskreductionsshown





screening methods have changed. Double view mammography




As with breast cancer mortality, our baseline risk of breast
cancer surgery was that for England in 1985. We assumed that
the risk increase shown in the trials applied to this risk.
Observational studies, including those summarised in the US
systematic review, provided a wide range of estimates of
overtreatment from 1%
7 to 52%
6 7 26-28 but have also been
criticised for poor quality.
29 We assigned a single loss of quality
oflifetoallformsofsurgerybutacknowledgethatlesserharms
arelikelywithlumpectomythanwithmastectomy.Againstthis,
we have not included the harms from radiotherapy and
chemotherapy. Future studies on quality of life might usefully
distinguish between the effects of different treatments.
How plausible are the losses in QALYs from surgery? The
Forrest report estimate of 8% seems to have been based on a
single small study from which it took the lowest estimate
30 (see
appendixonbmj.com).A2010systematicreviewofhealthstate
utilities in breast cancer
15 found only two relevant studies. One
putthelossinutilityat8%inyearone,4%ininterveningyears,
and 11% in the last year of life. The other put the loss at 38%
in year one after diagnosis, 31% in years one to five, and 29%
after five years. The 2010 UK COMICE trial put the loss in
quality of life from surgery in 1625 women with a low risk
breast cancer at 5% after 12 months.
12 The five year follow-up
to the PRIME trial showed that the quality of life losses after
surgery were unchanged after five years.
13 Overall, our
assumption of a permanent 6% loss in quality of life from
surgery does not seem unreasonable, but more robust estimates
are needed.
We assumed the base case to be a loss in quality of life from
false positive results of 5% of full health for 0.2 years. This is
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17 The 2010 systematic review of the utility losses from
breast cancer included estimates of this loss of between 11%
and 34%
15 but warned that the studies could not be synthesised.
The time frame of up to 20 years is long relative to the duration
of the trials, results of which have been synthesised up to 13
years.Extrapolationrequiredanassumptionofconstantbenefits
and harms from additional rounds of screening. Longer time
frames generate greater net QALYs but rely on increasingly
strong assumptions, both to do with the rate of survival from
breast cancer and the pattern of losses in quality of life over
time.
We assumed no recurrence of cancer, despite the 10 year
survival rate for breast cancer being 72% in the UK.
30 We also
assumed no re-operations, even though 17% of women with
tumours detected at screening in the UK had more than one
therapeuticoperationin2006-7.
31Whileitispossiblethatsome
cancers that were detected early by screening might have
progressed in longer time frames, a recent analysis has shown
no decline in the incidence of advanced breast cancer.
32
Modelling the longer term effects of breast cancer screening
should include these factors.
Finally, our list of benefits and harms excluded the potential
reassurance from a negative result on mammography. As a
negativemammogramhaslittlepredictivevalue,anyreassurance
is limited to relief at not having cancer at that time.
33 The 2010
systematic review of utility states in breast cancer
15 found no
evidence of improved quality of life from negative results.
Comparison with other studies
Our results can be compared with attempts to model the
effectiveness of mammographic screening in terms of cost per
QALY. Although Stout et al
16 included only losses of quality
of life in a sensitivity analysis, their inclusion roughly doubled
the cost per QALY. The Dutch MISCAN study concluded that
including the effects on quality of life of both treatment and
false positive results had little consequence,
17 but this seems to
bebecauseoftherelativelylowlevelofsurgeryassumedinthat
model. In a review of the cost effectiveness of extending the
age range for the UK breast screening programme, Madan et
al
18 showed that inclusion of losses of quality of life from false
positive results considerably increased the cost per QALY.
Conclusions and policy implications
Overall, our study supports the suggestion by Gøtzsche and
Nielsen that mammographic breast cancer screening could be
causing more harm than good after 10 years.
6 Scenario 4, based
on Gotzsche and Nielsen’s best estimate, had negative QALYs
for the first seven years after screening and minimal gains of
70 QALYs after 10 years. Thereafter, net QALYs accumulate
but much less than would be expected by our updating of the
Forrest report. The uncertainty around this result, explored in
scenarios3and5andingreaterdetailinotherscenarios,applies
more to the longer than the shorter term. Harms largely offset
the gains up to 10 years, after which the gains accumulate at an
increasing rate.
Moreresearchisrequiredontheextentofunnecessarytreatment
and its impact on quality of life. Most of the observational
studies of overtreatment have focused on the relation between
the incidence of breast cancer and mortality rather than on the
levels of treatment, especially surgery. The effects of treatment
on quality of life could be established observationally or in
longerfollow-upstudiesoftrials.
13Improvedwaysofidentifying




of overtreatment, researchers in countries that have not yet
implementedbreastcancerscreeningshouldconsidertrialsthat
include the harms of screening. There have been suggestions
for more sophisticated approaches to the prevention and
treatment of breast cancer.
33 34 From a public perspective, the
meaning and implications of overdiagnosis and overtreatment
need to be much better explained and communicated to any
woman considering screening.
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RESEARCHTables
Table 1| Data used to estimate QALYs for mammographic breast cancer screening of women aged 50, by scenario
Sources Value Parameter and scenario
Relative risk reduction in mortality from breast cancer:
Forrest report
1 −30% for 10 years, 0% thereafter Scenario 1
Gøtzsche and Nielsen Cochrane review
6 −19% Scenarios 2-3
Gøtzsche and Nielsen Cochrane Review
6 −15% Scenario 4
Nelson et al, US systematic review





14 6.39% at 1st invitation; 3.06% at 2nd and subsequent invitation All scenarios






−5% Loss of quality of life
0.2 Duration of loss (years)
Breast cancer surgery:
Gøtzsche and Nielsen Cochrane review
6 35% (26% to 44%) Relative risk
Loss of quality of life:
Forrest report




17 −6% for all who had surgery Scenarios 3, 4, 5
COMICE trial








Permanent in base case
6 Duration of loss
5 and 10 years’ duration Sensitivity analyses
NHS mortality statistics for 1985, England
9 Rates per 100 000: 73.65 at age 50-54, 97.55 at age 55-59,
117.47 at age 60-64, 123.03 at age 65-69
Baseline mortality from breast cancer
HIPE for England 1985
10 11 Rate per 100 000: 438.01 aged 45-64 Baseline risk of breast cancer surgery
Advisory Committee on Breast Cancer Screening
19 73.2% Screening attendance rate
— 0-20 years, scenarios (except scenarios with 5 and 10 year
duration)
Time frame
QALY=quality adjusted life year.
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RESEARCHTable 2| Net QALYs gained over time in women undergoing breast screening by scenario
At 20 years At 10 years At 5 years Scenario
3301 1189 304 1. Original Forrest report
3145 764 195 2. As 1 updated for breast cancer mortality from eight trials
1536 240 12 3. As 2 with harms added
834 70 −31 4. As 3 but with mortality suggested by Gøtzsche and Nielsen
6
1685 27 −42 5. As 3 but baseline mortality and reductions as in Nelson et al
7 8
QALY=quality adjusted life year.
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RESEARCHFigures
Fig 1 Outline of Southampton breast screening model: this applies to two cohorts of women aged 50, one screened the
other not
Fig 2 Breast cancer screening over 20 years: net QALYs by year after start of screening according to different scenarios
Fig 3 Probabilistic sensitivity analysis, including reduced mortality from breast cancer, increased surgery for breast cancer,
and losses of quality of life from false positive results and from surgery, showing cumulative QALYs for 100 000 iterations,
scenario 3 (Forrest updated with harms)
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